IN THIS SECTION: ALSO IN THIS SECTION:

DOSING AND ADMINISTRATION^1,2

IN THIS SECTION: ALSO IN THIS SECTION:

Dosing information

For oral use. Patients should be instructed to swallow the tablets whole
TRIKAFTA^® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) should be taken with fat-containing meals or snacks. Examples include food prepared with butter or oils or those containing eggs, cheeses, nuts, whole milk, or meats
Food or drink containing grapefruit should be avoided during treatment with TRIKAFTA

**← ~12 hours apart →**
	MORNING	EVENING
Patients aged 6 through 11 years weighing <30 kg (<66 lb)
RECOMMENDED DOSAGE	elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg/ 2 light orange tablets	ivacaftor 75 mg 1 light blue tablet
Patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older
RECOMMENDED DOSAGE	elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets	ivacaftor 150 mg 1 light blue tablet

In patients with severe hepatic impairment (Child-Pugh Class C)	SHOULD NOT BE USED
In patients with moderate hepatic impairment (Child-Pugh Class B)	USE SHOULD ONLY BE CONSIDERED WHEN THERE IS A CLEAR MEDICAL NEED AND THE BENEFIT EXCEEDS THE RISK^a,b
Strong CYP3A inducers including: rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, St. John’s wort ( Hypericum perforatum)	CONCOMITANT USE NOT RECOMMENDED
Strong CYP3A inhibitors including: ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin	For patients aged 6 through 11 years weighing <30 kg (<66 lb) IN THE MORNING (TWICE A WEEK) DAY 1 elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets DAY 4^c elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older IN THE MORNING (TWICE A WEEK) DAY 1 elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets DAY 4^c elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets	NO TABLET IN THE EVENING
Moderate CYP3A inhibitors including: fluconazole, erythromycin	For patients aged 6 through 11 years weighing <30 kg (<66 lb) ALTERNATE TABLETS EVERY MORNING DAY 1 elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets DAY 2^d ivacaftor 75 mg 1 light blue tablet For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older ALTERNATE TABLETS EVERY MORNING DAY 1 elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets DAY 2^d ivacaftor 150 mg 1 light blue tablet	NO TABLET IN THE EVENING

**← ~12 hours apart →**
MORNING	EVENING

Patients aged 6 through 11 years weighing <30 kg (<66 lb)
RECOMMENDED DOSAGE
elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets	ivacaftor 75 mg 1 light blue tablet
Patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older
RECOMMENDED DOSAGE
elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets	ivacaftor 150 mg 1 light blue tablet

In patients with severe hepatic impairment (Child-Pugh Class C)
SHOULD NOT BE USED

In patients moderate hepatic impairment (Child-Pugh Class B)
USE SHOULD ONLY BE CONSIDERED WHEN THERE IS A CLEAR MEDICAL NEED AND THE BENEFIT EXCEEDS THE RISK^a,b

Strong CYP3A inducers including: rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, St. John’s wort (Hypericum perforatum)
CONCOMMITANT USE NOT RECOMMENDED

Strong CYP3A inhibitors including: ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin
For patients aged 6 through 11 years weighing <30 kg (<66 lb) IN THE MORNING (TWICE A WEEK) DAY 1 elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets DAY 4^c elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older IN THE MORNING (TWICE A WEEK) DAY 1 elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets DAY 4^c elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets	NO TABLET IN THE EVENING

Moderate CYP3A inhibitors including: fluconazole, erythromycin
For patients aged 6 through 11 years weighing <30 kg (<66 lb) ALTERNATE TABLETS EVERY MORNING DAY 1 elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets DAY 2^d ivacaftor 75 mg 1 light blue tablet For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and and older ALTERNATE TABLETS EVERY MORNING DAY 1 elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets DAY 2^d ivacaftor 150 mg 1 light blue tablet	NO TABLET IN THE EVENING

← ~12 hours apart →

	MORNING	EVENING
Patients aged 6 through 11 years weighing <30 kg (<66 lb)
RECOMMENDED DOSAGE	elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg/ 2 light orange tablets	ivacaftor 75 mg 1 light blue tablet
Patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older
RECOMMENDED DOSAGE	elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets	ivacaftor 150 mg 1 light blue tablet

In patients with severe hepatic impairment (Child-Pugh Class C)	SHOULD NOT BE USED
In patients with moderate hepatic impairment (Child-Pugh Class B)	USE SHOULD ONLY BE CONSIDERED WHEN THERE IS A CLEAR MEDICAL NEED AND THE BENEFIT EXCEEDS THE RISK^a,b
Strong CYP3A inducers including: rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, St. John’s wort (Hypericum perforatum)	CONCOMITANT USE NOT RECOMMENDED
Strong CYP3A inhibitors including: ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin	For patients aged 6 through 11 years weighing <30 kg (<66 lb) IN THE MORNING (TWICE A WEEK) DAY 1 elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets DAY 4^c elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older IN THE MORNING (TWICE A WEEK) DAY 1 elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets DAY 4^c elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets	NO TABLET IN THE EVENING
Moderate CYP3A inhibitors including: fluconazole, erythromycin	For patients aged 6 through 11 years weighing <30 kg (<66 lb) ALTERNATE TABLETS EVERY MORNING DAY 1 elexacaftor 50 mg/ tezacaftor 25 mg/ ivacaftor 37.5 mg 2 light orange tablets DAY 2^d ivacaftor 75 mg 1 light blue tablet For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older ALTERNATE TABLETS EVERY MORNING DAY 1 elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg 2 orange tablets DAY 2^d ivacaftor 150 mg 1 light blue tablet	NO TABLET IN THE EVENING

Tablets are not actual size.

ᵃLiver function tests should be closely monitored.¹

^aLiver function tests should be closely monitored.¹

ᵃLiver function tests should be closely monitored.¹

^bTRIKAFTA is not recommended for patients with moderate hepatic impairment. If TRIKAFTA is used in patients with moderate hepatic impairment, it should be with caution and at a reduced dose, as follows¹:

Day 1: Patients should take 2 elexacaftor/tezacaftor/ivacaftor tablets in the morning
Day 2: Patients should take 1 elexacaftor/tezacaftor/ivacaftor tablet in the morning
Continue alternating Day 1 and Day 2 dosing thereafter
No evening dose of ivacaftor should be taken

Day 1: Patients should take 2 elexacaftor/tezacaftor/ivacaftor tablets in the morning
Day 2: Patients should take 1 elexacaftor/tezacaftor/ivacaftor tablet in the morning
Continue alternating Day 1 and Day 2 dosing thereafter
No evening dose of ivacaftor should be taken

Day 1: Patients should take 2 elexacaftor/tezacaftor/ivacaftor tablets in the morning
Day 2: Patients should take 1 elexacaftor/tezacaftor/ivacaftor tablet in the morning
Continue alternating Day 1 and Day 2 dosing thereafter
No evening dose of ivacaftor should be taken

^cContinue dosing with 2 elexacaftor/tezacaftor/ivacaftor tablets twice a week, approximately 3 to 4 days apart.¹

^dContinue dosing with 2 elexacaftor/tezacaftor/ivacaftor tablets and 1 ivacaftor tablet on alternate days.¹

^cContinue dosing with 2 elexacaftor/tezacaftor/ivacaftor tablets twice a week, approximately 3 to 4 days apart.¹

^dContinue dosing with 2 elexacaftor/tezacaftor/ivacaftor tablets and 1 ivacaftor tablet on alternate days.¹

^cContinue dosing with 2 elexacaftor/tezacaftor/ivacaftor tablets twice a week, approximately 3 to 4 days apart.¹

^dContinue dosing with 2 elexacaftor/tezacaftor/ivacaftor tablets and 1 ivacaftor tablet on alternate days.¹

No dose adjustment is required for patients with mild hepatic impairment. Liver function tests should be closely monitored¹
TRIKAFTA has not been studied in patients with severe hepatic impairment, but the exposure is expected to be higher than in patients with moderate hepatic impairment. TRIKAFTA should not be used in patients with severe hepatic impairment¹
No dose adjustment is recommended in patients with mild or moderate renal impairment TRIKAFTA has not been studied in patients with severe renal impairment or end stage renal disease and should be used with caution in these patients¹

No dose adjustment is required for patients with mild hepatic impairment. Liver function tests should be closely monitored¹
TRIKAFTA has not been studied in patients with severe hepatic impairment, but the
exposure is expected to be higher than in patients with moderate hepatic impairment. TRIKAFTA should not be used in patients with severe hepatic impairment¹
No dose adjustment is recommended in patients with mild or moderate renal impairment TRIKAFTA has not been studied in patients with severe renal impairment or end stage renal disease and should be used with caution in these patients¹

No dose adjustment is required for patients with mild hepatic impairment. Liver function tests should be closely monitored¹
TRIKAFTA has not been studied in patients with severe hepatic impairment, but the
exposure is expected to be higher than in patients with moderate hepatic impairment.
TRIKAFTA should not be used in patients with severe hepatic impairment¹
No dose adjustment is recommended in patients with mild or moderate renal impairment
TRIKAFTA has not been studied in patients with severe renal impairment or end stage renal
disease and should be used with caution in these patients¹

MISSED DOSE¹

MISSED MORNING DOSE

If ≤6 hours have passed, take as soon as possible and take evening dose as scheduled
If >6 hours have passed, take the missed dose as soon as possible but do not take evening dose and continue as scheduled the following day

MISSED EVENING DOSE

If ≤6 hours have passed, take as soon as possible and take next morning dose as scheduled
If >6 hours have passed, do not take missed dose and take next morning dose as scheduled the following day

Morning and evening doses should not be taken at the same time

MISSED DOSE¹

MISSED MORNING DOSE

If ≤6 hours have passed, take as soon as possible and take evening dose as scheduled
If >6 hours have passed, take the missed dose as soon as possible but do not take evening dose and continue as scheduled the following day

MISSED EVENING DOSE

If ≤6 hours have passed, take as soon as possible and take next morning dose as scheduled
If >6 hours have passed, do not take missed dose and take next morning dose as scheduled the following day

Morning and evening doses should not be taken at the same time

TRIKAFTA is supplied in cartons containing 4 weekly wallets, each with 21 tablets^1,2

For patients aged 6 through 11 years weighing <30 kg (<66 lb)

For patients aged 6 through
11 years weighing <30 kg (<66 lb)

Not actual size.

TRIKAFTA is a co-package of fixed-dose combination tablets containing elexacaftor
50 mg, tezacaftor 25 mg, and ivacaftor 37.5 mg, and ivacaftor 75 mg tablets
- The elexacaftor, tezacaftor, and ivacaftor tablets are light orange, capsule-shaped, and debossed with "T50" on one side and plain on the other
- The ivacaftor tablets are light blue, capsule-shaped, and printed with "V 75" in black ink on one side and plain on the other

For patients aged 6 through 11 years weighing <30 kg (<66 lb)

For patients aged 6 through
11 years weighing <30 kg (<66 lb)

Not actual size.

TRIKAFTA is a co-package of fixed-dose combination tablets containing elexacaftor
50 mg, tezacaftor 25 mg, and ivacaftor 37.5 mg, and ivacaftor 75 mg tablets
- The elexacaftor, tezacaftor, and ivacaftor tablets are light orange, capsule-shaped, and debossed with "T50" on one side and plain on the other
- The ivacaftor tablets are light blue, capsule-shaped, and printed with "V 75" in black ink on one side and plain on the other

For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older

For patients aged 6 through
11 years weighing ≥30 kg (≥66 lb) and
12 years and older

Not actual size.

TRIKAFTA is a co-package of fixed-dose combination tablets containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg, and ivacaftor 150 mg tablets
- The elexacaftor, tezacaftor, and ivacaftor tablets are orange, capsule-shaped, and debossed with "T100" on one side and plain on the other
- The ivacaftor tablets are light blue, capsule-shaped, and printed with "V 150" in black ink on one side and plain on the other

For patients aged 6 through 11 years weighing ≥30 kg (≥66 lb) and 12 years and older

For patients aged 6 through
11 years weighing ≥30 kg (≥66 lb) and
12 years and older

Not actual size.

TRIKAFTA is a co-package of fixed-dose combination tablets containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg, and ivacaftor 150 mg tablets
- The elexacaftor, tezacaftor, and ivacaftor tablets are orange, capsule-shaped, and debossed with "T100" on one side and plain on the other
- The ivacaftor tablets are light blue, capsule-shaped, and printed with "V 150" in black ink on one side and plain on the other

lb, pounds.

See potential drug-drug interactions

View the clinical trials of TRIKAFTA

Important Safety Information

Elevated Transaminases and Hepatic Injury

Liver failure leading to transplantation has been reported in a patient with cirrhosis and portal hypertension while receiving TRIKAFTA. Avoid use of TRIKAFTA in patients with pre-existing advanced liver disease (e.g., as evidenced by cirrhosis, portal hypertension, ascites, hepatic encephalopathy) unless the benefits are expected to outweigh the risks. If used in these patients, they should be closely monitored after the initiation of treatment

Isolated elevations of transaminases or bilirubin have been observed in patients with CF treated with TRIKAFTA. In some instances, transaminase elevations have been associated with concomitant elevations in total bilirubin and/or international normalized ratio (INR) and have resulted in patients being hospitalized for intervention, including in patients without a history of pre-existing liver disease

Indications and Usage

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data.

Assessments of liver function tests (ALT, AST, and bilirubin) are recommended prior to initiating TRIKAFTA, every 3 months during the first year of treatment, and annually thereafter

In the event of significant elevations in liver function tests, e.g. ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN, dosing should be interrupted and laboratory tests closely followed until the abnormalities resolve. Following the resolution of liver function test elevations, consider the benefits and risks of resuming treatment

For patients with a history of hepatobiliary disease or liver function test elevations, more frequent monitoring should be considered

Concomitant Use With CYP3A Inducers

Exposure to ivacaftor is significantly decreased and exposure to elexacaftor and tezacaftor are expected to decrease by the concomitant use of strong CYP3A inducers, which may reduce the therapeutic effectiveness of TRIKAFTA. Co‑administration with strong CYP3A inducers is not recommended

Concomitant Use With CYP3A Inhibitors

Exposure to elexacaftor, tezacaftor, and ivacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors

Cataracts

Cases of non-congenital lens opacities have been reported in pediatric patients treated with ivacaftor-containing regimens. Baseline and follow up ophthalmological examinations are recommended in pediatric patients initiating treatment with TRIKAFTA

Pediatric Use

The safety and effectiveness of TRIKAFTA in patients with CF younger than 6 years of age have not been established

Serious Adverse Reactions

Serious adverse reactions that occurred more frequently in patients treated with TRIKAFTA compared to placebo were rash (1% vs <1%) and influenza (1% vs 0)

Most Common Adverse Reactions

The most common adverse reactions occurring in ≥5% of patients treated with TRIKAFTA (N=202) and higher than placebo (N=201) by ≥1% in the 24-week placebo-controlled, parallel-group Phase 3 trial (Trial 1) were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, and blood bilirubin increased
The safety profile for the patients with CF receiving TRIKAFTA (N=55) enrolled in the 4-week, randomized, double-blind, active-controlled Phase 3 trial (Trial 2) was similar to that observed in Trial 1
The safety profile in patients age 6 to less than 12 years from an open-label Phase 3 trial (N=66) was similar to that observed in trials of patients age 12 years and older

Click here to access full Prescribing Information for TRIKAFTA.

References:

1. TRIKAFTA [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; October 2021. 2. Data on file. Vertex Pharmaceuticals Incorporated. Boston, MA. REF-6607 (v2.0); 2021.

EXPAND

COLLAPSE

Indications and Usage TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data.

Indications and Usage

Important Safety Information

Elevated Transaminases and Hepatic Injury

Liver failure leading to transplantation has been reported in a patient with cirrhosis and portal hypertension while receiving TRIKAFTA. Avoid use of TRIKAFTA in patients with pre-existing advanced liver disease (e.g., as evidenced by cirrhosis, portal hypertension, ascites, hepatic encephalopathy) unless the benefits are expected to outweigh the risks. If used in these patients, they should be closely monitored after the initiation of treatment
Isolated elevations of transaminases or bilirubin have been observed in patients with CF treated with TRIKAFTA. In some instances, transaminase elevations have been associated with concomitant elevations in total bilirubin and/or international normalized ratio (INR) and have resulted in patients being hospitalized for intervention, including in patients without a history of pre-existing liver disease

Indications and Usage

Important Safety Information

Elevated Transaminases and Hepatic Injury

Liver failure leading to transplantation has been reported in a patient with cirrhosis and portal hypertension while receiving TRIKAFTA. Avoid use of TRIKAFTA in patients with pre-existing advanced liver disease (e.g., as evidenced by cirrhosis, portal hypertension, ascites, hepatic encephalopathy) unless the benefits are expected to outweigh the risks. If used in these patients, they should be closely monitored after the initiation of treatment
Isolated elevations of transaminases or bilirubin have been observed in patients with CF treated with TRIKAFTA. In some instances, transaminase elevations have been associated with concomitant elevations in total bilirubin and/or international normalized ratio (INR) and have resulted in patients being hospitalized for intervention, including in patients without a history of pre-existing liver disease
Assessments of liver function tests (ALT, AST, and bilirubin) are recommended prior to initiating TRIKAFTA, every 3 months during the first year of treatment, and annually thereafter
In the event of significant elevations in liver function tests, e.g. ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN, dosing should be interrupted and laboratory tests closely followed until the abnormalities resolve. Following the resolution of liver function test elevations, consider the benefits and risks of resuming treatment
For patients with a history of hepatobiliary disease or liver function test elevations, more frequent monitoring should be considered

Concomitant Use With CYP3A Inducers

Exposure to ivacaftor is significantly decreased and exposure to elexacaftor and tezacaftor are expected to decrease by the concomitant use of strong CYP3A inducers, which may reduce the therapeutic effectiveness of TRIKAFTA. Co‑administration with strong CYP3A inducers is not recommended

Concomitant Use With CYP3A Inhibitors

Exposure to elexacaftor, tezacaftor, and ivacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors

Cataracts

Cases of non-congenital lens opacities have been reported in pediatric patients treated with ivacaftor-containing regimens. Baseline and follow up ophthalmological examinations are recommended in pediatric patients initiating treatment with TRIKAFTA

Pediatric Use

The safety and effectiveness of TRIKAFTA in patients with CF younger than 6 years of age have not been established

Serious Adverse Reactions

Serious adverse reactions that occurred more frequently in patients treated with TRIKAFTA compared to placebo were rash (1% vs <1%) and influenza (1% vs 0)

Most Common Adverse Reactions

The most common adverse reactions occurring in ≥5% of patients treated with TRIKAFTA (N=202) and higher than placebo (N=201) by ≥1% in the 24-week placebo-controlled, parallel-group Phase 3 trial (Trial 1) were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, and blood bilirubin increased
The safety profile for the patients with CF receiving TRIKAFTA (N=55) enrolled in the 4-week, randomized, double-blind, active-controlled Phase 3 trial (Trial 2) was similar to that observed in Trial 1
The safety profile in patients age 6 to less than 12 years from an open-label Phase 3 trial (N=66) was similar to that observed in trials of patients age 12 years and older

Click here to access full Prescribing Information for TRIKAFTA.

References:

1. TRIKAFTA [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; October 2021. 2. Data on file. Vertex Pharmaceuticals Incorporated. Boston, MA. REF-6607 (v2.0); 2021.

Assessments of liver function tests (ALT, AST, and bilirubin) are recommended prior to initiating TRIKAFTA, every 3 months during the first year of treatment, and annually thereafter
In the event of significant elevations in liver function tests, e.g. ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN, dosing should be interrupted and laboratory tests closely followed until the abnormalities resolve. Following the resolution of liver function test elevations, consider the benefits and risks of resuming treatment
For patients with a history of hepatobiliary disease or liver function test elevations, more frequent monitoring should be considered

Concomitant Use With CYP3A Inducers

Exposure to ivacaftor is significantly decreased and exposure to elexacaftor and tezacaftor are expected to decrease by the concomitant use of strong CYP3A inducers, which may reduce the therapeutic effectiveness of TRIKAFTA. Co‑administration with strong CYP3A inducers is not recommended

Concomitant Use With CYP3A Inhibitors

Exposure to elexacaftor, tezacaftor, and ivacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors

Cataracts

Cases of non-congenital lens opacities have been reported in pediatric patients treated with ivacaftor-containing regimens. Baseline and follow up ophthalmological examinations are recommended in pediatric patients initiating treatment with TRIKAFTA

Pediatric Use

The safety and effectiveness of TRIKAFTA in patients with CF younger than 6 years of age have not been established

Serious Adverse Reactions

Serious adverse reactions that occurred more frequently in patients treated with TRIKAFTA compared to placebo were rash (1% vs <1%) and influenza (1% vs 0)

Most Common Adverse Reactions

The most common adverse reactions occurring in ≥5% of patients treated with TRIKAFTA (N=202) and higher than placebo (N=201) by ≥1% in the 24-week placebo-controlled, parallel-group Phase 3 trial (Trial 1) were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, and blood bilirubin increased
The safety profile for the patients with CF receiving TRIKAFTA (N=55) enrolled in the 4-week, randomized, double-blind, active-controlled Phase 3 trial (Trial 2) was similar to that observed in Trial 1
The safety profile in patients age 6 to less than 12 years from an open-label Phase 3 trial (N=66) was similar to that observed in trials of patients age 12 years and older

Click here to access full Prescribing Information for TRIKAFTA.

References:

1. TRIKAFTA [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; October 2021. 2. Data on file. Vertex Pharmaceuticals Incorporated. Boston, MA. REF-6607 (v2.0); 2021.

DOSING AND ADMINISTRATION1,2

DOSING AND ADMINISTRATION^1,2